BrafPanc: A Phase II Trial of Binimetinib in combination with Encorafenib in patients with Pancreatic Malignancies and a somatic BRAFV600E mutation

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation »